ID: h-debate-624ccea7e1e9
Hypothesis

Neuroinflammation Biomarker-Guided Immunomodulation for GBA Carriers

Early-stage immunomodulatory therapy guided by inflammatory biomarkers could prevent transition from GBA carrier status to clinical Parkinson's disease.
🧬 IL1B🎯 Composite 0%💱 $0.51▲1.1%proposed
neurodegeneration
EvidenceModerate (50%)📖 0 cit🗣 1 debates 1 support 0 oppose
✓ All Quality Gates Passed
Mechanistic 0.60 (15%) Evidence 0.55 (15%) Novelty 0.60 (12%) Feasibility 0.00 (12%) Impact 0.00 (12%) Druggability 0.00 (10%) Safety 0.00 (8%) Competition 0.00 (6%) Data Avail. 0.00 (5%) Reproducible 0.00 (5%) KG Connect 0.50 (8%) 0.000 composite

🧪 Overview

Early-stage immunomodulatory therapy guided by inflammatory biomarkers could prevent transition from GBA carrier status to clinical Parkinson's disease.

Debate provenance: derived from debate `sess_SDA-2026-04-10-gba-pd` on question: GBA-Synuclein Loop: Therapeutic Strategies for Parkinson's Disease?. Consensus signal: domain_expert, skeptic, synthesizer, theorist discussed the mechanism terms Biomarker-Guided, Carriers, GBA, IL1B, Immunomodulation, Neuroinflammation, modulation, neuroinflammation. Novelty signal: skeptic-discussed-with-qualified-concession.

🧬 Mechanism

🔗 Mechanism from KG for IL1B

Auto-built from this analysis's top knowledge-graph edges.

graph TD
    GBA_mutations["GBA mutations"] -->|associated with| Parkinson_s_disease["Parkinson's_disease"]
    GBA["GBA"] -->|encodes| glucocerebrosidase["glucocerebrosidase"]
    glucocerebrosidase_1["glucocerebrosidase"] -->|associated with| Alpha_Synuclein_Accumulat["Alpha-Synuclein Accumulation"]
    GBA_deficiency["GBA deficiency"] -->|causes| Alpha_Synuclein_Accumulat_2["Alpha-Synuclein Accumulation"]
    alpha_synuclein_aggregate["alpha-synuclein aggregates"] -->|causes| glucocerebrosidase_dysfun["glucocerebrosidase dysfunction"]
    TFEB["TFEB"] -->|activates| lysosomal_biogenesis["lysosomal_biogenesis"]
    autophagy_pathway["autophagy_pathway"] -->|regulates| lysosomal_degradation["lysosomal degradation"]
    TFEB_activation["TFEB activation"] -->|enhances| alpha_synuclein_clearance["alpha-synuclein clearance"]
    TFEB_activation_3["TFEB activation"] -->|associated with| GBA_enzyme_function["GBA enzyme function"]
    mTORC1_inhibitors["mTORC1 inhibitors"] -->|activates| TFEB_4["TFEB"]
    Ampk_Activators["Ampk Activators"] -->|activates| TFEB_5["TFEB"]
    neuroinflammation["neuroinflammation"] -->|associated with| GBA_carrier_to_PD_progres["GBA carrier to PD progression"]
    style GBA_mutations fill:#ce93d8,stroke:#333,color:#000
    style Parkinson_s_disease fill:#ef5350,stroke:#333,color:#000
    style GBA fill:#ce93d8,stroke:#333,color:#000
    style glucocerebrosidase fill:#4fc3f7,stroke:#333,color:#000
    style glucocerebrosidase_1 fill:#4fc3f7,stroke:#333,color:#000
    style Alpha_Synuclein_Accumulat fill:#4fc3f7,stroke:#333,color:#000
    style GBA_deficiency fill:#4fc3f7,stroke:#333,color:#000
    style Alpha_Synuclein_Accumulat_2 fill:#4fc3f7,stroke:#333,color:#000
    style alpha_synuclein_aggregate fill:#4fc3f7,stroke:#333,color:#000
    style glucocerebrosidase_dysfun fill:#4fc3f7,stroke:#333,color:#000
    style TFEB fill:#ce93d8,stroke:#333,color:#000
    style lysosomal_biogenesis fill:#4fc3f7,stroke:#333,color:#000
    style autophagy_pathway fill:#81c784,stroke:#333,color:#000
    style lysosomal_degradation fill:#4fc3f7,stroke:#333,color:#000
    style TFEB_activation fill:#4fc3f7,stroke:#333,color:#000
    style alpha_synuclein_clearance fill:#4fc3f7,stroke:#333,color:#000
    style TFEB_activation_3 fill:#4fc3f7,stroke:#333,color:#000
    style GBA_enzyme_function fill:#4fc3f7,stroke:#333,color:#000
    style mTORC1_inhibitors fill:#4fc3f7,stroke:#333,color:#000
    style TFEB_4 fill:#ce93d8,stroke:#333,color:#000
    style Ampk_Activators fill:#4fc3f7,stroke:#333,color:#000
    style TFEB_5 fill:#4fc3f7,stroke:#333,color:#000
    style neuroinflammation fill:#4fc3f7,stroke:#333,color:#000
    style GBA_carrier_to_PD_progres fill:#4fc3f7,stroke:#333,color:#000

⚖️ Evidence

📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — IL1B

🧬 PDB 1I1B Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for IL1B →

No DepMap CRISPR Chronos data found for IL1B.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0002
Events (7d)
1
Price History
▲1.1%

💾 Resource Usage

LLM Tokens
15,800
$0.0948
Total Cost
$0.0948
Metadatasource: v1_phase_c_backfill · origin_type: debate_round_mining
sourcev1_phase_c_backfill
origin_typedebate_round_mining
_schema_version1
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting 0 contradicting 0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.